COVID-19’s Early Financing Fallout

article image
ARTICLE SUMMARY:

Venture-backed medtech companies are taking a pounding from COVID-19, and while VCs initially are pausing investment as they scramble to manage their portfolios through the chaos, they should find buying opportunities, particularly among later-stage companies.

As late as early March, 2020 looked to be a banner year for medtech venture financing. Now, the sector, along with much of the rest of the world, has come to a screeching halt and is clumsily digging out of an unprecedented economic and health disaster.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: